Secukinumab in Moderate-to-Severe Graves Orbitopathy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter...

Area of Science:

• Ophthalmology
• Immunology
• Endocrinology

Background:

• Interleukin 17 (IL-17) is a pro-inflammatory cytokine implicated in Graves' orbitopathy (GO) pathogenesis.
• Elevated IL-17 and Th17 cells correlate with GO disease activity and severity.

Purpose of the Study:

• To evaluate the efficacy and safety of secukinumab, an IL-17A inhibitor, in patients with active, moderate-to-severe GO.
• The ORBIT study assessed secukinumab's impact on clinical activity and proptosis in GO.

Main Methods:

• A randomized, double-blind, placebo-controlled, multicenter trial.
• Adults with active, moderate-to-severe GO received secukinumab 300 mg or placebo subcutaneously for 16 weeks.
• The primary endpoint was an overall response defined by reduced clinical activity score (CAS) and proptosis.

Main Results:

• Twenty-eight GO patients were enrolled; none achieved an overall response in either the secukinumab or placebo groups.
• No clinically meaningful changes were observed in ophthalmic symptoms, proptosis, or quality of life.
• Secukinumab was well-tolerated with mild adverse events and no new safety signals.

Conclusions:

• Secukinumab did not demonstrate clinical efficacy compared to placebo in patients with active, moderate-to-severe GO.
• The study suggests IL-17A inhibition may not be an effective therapeutic strategy for this condition.